ERAS-0015

July 13, 2026: Erasca, Inc. (NASDAQ: ERAS) reported updated preliminary Phase 1 data from the ongoing AURORAS-1 trial of ERAS-0015 (oral pan-RAS molecular glue) in RAS-mutant solid tumors and outlined planned registration-enabling development.

ERAS-0015 monotherapy (2L+ KRAS G12X PDAC, U.S. trial): At the recommended dose for expansion (RDE) of 32 mg QD, uORR at 8 weeks was 57% (N=7; data cutoff May 25, 2026). Across doses, all patients with confirmed or unconfirmed responses remained on treatment; 6/7 remained on treatment at 32 mg and 6/8 at 24 mg.

Safety (monotherapy): Generally well-tolerated with mostly low-grade TRAEs; no dose-limiting toxicities, low rates of dose interruptions/reductions, and no discontinuations due to TRAEs. Median relative dose intensity was 100% at both 24 mg and 32 mg.

Combination (metastatic CRC): In dose escalation with panitumumab, no DLTs were observed in the ERAS-0015 16 mg cohort (4 DLT-evaluable; DCO July 6, 2026). Backfill at 16 mg and dose escalation at 24 mg are ongoing.

Upcoming catalysts: Additional ERAS-0015 monotherapy and panitumumab-combination data expected H1 2027; planned trials include a potentially registration-enabling 2L+ NSCLC trial (H1 2027), a 1L PDAC Phase 3 pivotal trial (2027), and a RAS-mutant NSCLC Phase 3 pivotal trial (H2 2027–H1 2028).